This $466,970 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Brigham & Women's Hospital to develop ultra-long-term intra-articular delivery of disease-modifying biologics to reduce the progression of post-traumatic osteoarthritis. The research, which will be conducted over a 2-year period from February 2025 to February 2027, aims to advance treatments for this common condition affecting military service members and the broader public. As a subsidiary of Partners Healthcare System, Brigham & Women's Hospital has a strong track record of conducting cutting-edge biomedical and clinical research through federal grants and contracts across a range of medical specialties.
Generated 3/4/25, 8:24 AM